Xeris Biopharma Holdings, Inc. Stock price

Equities

XERS

US98422E1038

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:35:21 2024-03-28 pm EDT 5-day change 1st Jan Change
2.185 USD +7.11% Intraday chart for Xeris Biopharma Holdings, Inc. +2.58% -7.02%
Sales 2024 * 184M Sales 2025 * 219M Capitalization 287M
Net income 2024 * -55M Net income 2025 * -27M EV / Sales 2024 * 1.55 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.31 x
P/E ratio 2024 *
-5.3 x
P/E ratio 2025 *
-11.1 x
Employees 377
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.13%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Xeris Biopharma Holdings, Inc.

1 day+7.11%
1 week+2.58%
Current month-28.94%
1 month-27.65%
3 months-7.42%
6 months+16.22%
Current year-7.02%
More quotes
1 week
2.00
Extreme 2
2.28
1 month
2.00
Extreme 2
3.26
Current year
2.00
Extreme 2
3.26
1 year
1.31
Extreme 1.31
3.26
3 years
0.97
Extreme 0.9701
3.26
5 years
0.97
Extreme 0.9701
3.26
10 years
0.97
Extreme 0.9701
3.26
More quotes
Managers TitleAgeSince
Founder 60 04-12-31
Chief Executive Officer 67 21-10-04
Director of Finance/CFO 47 20-12-31
Members of the board TitleAgeSince
Director/Board Member 66 21-10-04
Director/Board Member 69 21-10-04
Director/Board Member 68 21-10-04
More insiders
Date Price Change Volume
24-03-28 2.2 +7.84% 2 277 648
24-03-27 2.04 -0.49% 1,611,445
24-03-26 2.05 -2.84% 1,102,864
24-03-25 2.11 +0.48% 1,387,087
24-03-22 2.1 -1.41% 901,331

Delayed Quote Nasdaq, March 28, 2024 at 01:20 pm EDT

More quotes
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which is focused on improving patients’ lives by developing and commercializing products across a range of therapies. It has three commercial products. Gvoke is a ready-to-use, liquid-stable glucagon for the treatment of severe hypoglycemia. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Keveyis is the first therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). It also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect. Its product candidate XP-8121, which is designed to be a once-weekly, small-volume, subcutaneous injection that bypasses the gastrointestinal tract and could avoid many therapeutic complications.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.04 USD
Average target price
4.75 USD
Spread / Average Target
+132.84%
Consensus
  1. Stock
  2. Equities
  3. Stock Xeris Biopharma Holdings, Inc. - Nasdaq